Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2011

01-10-2011

Soft Tissue Infections Caused by Marine Bacterial Pathogens: Epidemiology, Diagnosis, and Management

Authors: Renato Finkelstein, Ilana Oren

Published in: Current Infectious Disease Reports | Issue 5/2011

Login to get access

Abstract

Skin and soft tissue infections (SSTIs) are one of the most common infection syndromes and may be caused by a large number of microorganisms. Some principles of aquatic injuries are different than those of land-based trauma. Wounds sustained in marine environment are exposed to a milieu of bacteria rarely encountered in different settings. These include Vibrio spp., Aeromonas spp., Shewanella spp., Erysipelothrix rhusiopathiae, Mycobacterium marinum, Streptococcus iniae, and other microbes. Failure to recognize and treat these uncommon pathogens in a timely manner may result in significant morbidity or death. These infections are frequently contracted as a result of recreational swimming, fishing injuries, or seafood handling. The spectrum of manifestations is wide, varying from cases of mild cellulitis, to severe life-threatening necrotizing fasciitis requiring radical surgery, to sepsis and death. This review will focus on the epidemiology, clinical manifestations, and treatment of SSTIs caused by the most important marine pathogens.
Literature
1.
• Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(Suppl 3):iii35–44. This is a recent and complete overview of complicated skin and soft tissue infection, including those caused by less common pathogens.PubMedCrossRef
2.
Di Nubile MJ, Lipsky BA. Complicated infections of the skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother. 2004;53 Suppl 2:ii37–50.CrossRef
3.
Stevens DL, Bisno AL, Chambers H, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373–406.PubMedCrossRef
4.
Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52 Suppl 1:i3–i17.PubMedCrossRef
5.
Pomeroy LR. The microbial food web. Oceanus. 1992;35(3):28–35.
6.
Haddad Jr V, Lupi O, Lonza JP, Tyring SK. Tropical dermatology: marine and aquatic dermatology. J Am Acad Dermatol. 2009;61:733–50.PubMedCrossRef
7.
Kueh CSW, Kutarski P, Brunton M. Contaminated marine wounds—the risk of acquiring acute bacterial infection from marine recreational beaches. J Appl Bacteriol. 1992;73:412–20.PubMed
8.
Auerbach PS, Yajko DM, Nassos PS, et al. Bacteriology of the marine environment: implications for clinical therapy. Ann Emerg Med. 1987;16:643–9.PubMedCrossRef
9.
Noonburg GE. Management of extremity trauma and related infections occurring in the aquatic environment. J Am Acad Orthop Surg. 2005;13:243–53.PubMed
10.
Reed KC, Crowel MC. Skin and soft tissue infections after injury in ocean: culture methods and antibiotic therapy for marine bacteria. Mil Med. 1999;164:198–201.PubMed
11.
Buck JD, Spotte S, Gadbaw JJ, Jr. Bacteriology of teeth from great white shark: potential medical implications for shark bite victims. J Clin Microbiol. 1984;849–51.
12.
Hlady WG, Klontz K. The epidemiology of Vibrio infections in Florida, 1981–1993. J Infect Dis. 1996;173:1176–83.PubMedCrossRef
13.
Blake P, Weaver R, Hollis D. Diseases of humans (other than cholera) caused by vibrio. Annu Rev Microbiol. 1980;34:341–67.PubMedCrossRef
14.
Feldhusen F. The role of seafood in bacterial foodbourne diseases. Microbes Infect. 2000;2:1651–60.PubMedCrossRef
15.
• Jones MK, Oliver JD. Vibrio vulnificus: disease and pathogenesis. Infect Immun. 2009;77:1723–33. This minireview includes an in-depth discussion on the physiologic characteristics of Vibrio vulnificus.PubMedCrossRef
16.
Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect. 2005;133:383–91.PubMedCrossRef
17.
• Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: An important cause of morbidity and mortality in the United States, 1997–2006. Clin Infect Dis. 2008;46:970–6. This study represents the largest series of nonfoodborne Vibrio infections (including soft tissue infections) reported. PubMedCrossRef
18.
Bisharat N, Agmon V, Finkelstein R, et al. Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group. Lancet. 1999;354:1421–4.PubMedCrossRef
19.
Park K-H, Jung S-I, Jung Y-S, et al. Marine bacteria as a leading cause of necrotizing fasciitis in coastal areas of South Korea. Am J Trop Med Hyg. 2009;80:646–50.PubMed
20.
Zaidenstein R, Sadik C, Lerner L, et al. Clinical characteristics and molecular subtyping of Vibrio vulnificus illnesses, Israel. Em Infect Dis. 2008;14:1875–82.CrossRef
21.
Koenig KL, Mueller J, Rose T. Vibrio vulnificus: hazard on half shell. West J Med. 1991;155:400–3.PubMed
22.
Amaro C, Biosca EG. Vibrio vulnificus biotype 2, pathogenic for eels, is also an opportunistic pathogen for humans. Appl Environ Microbiol. 1996;62:1454–7.PubMed
23.
Tison DL, Nishibuchi M, Greenwood JD, Seidler RJ. Vibrio vulnificus biogroup 2: new biogroup pathogenic for eels. Appl Environ Microbiol. 1982;44:640–6.PubMed
24.
Chuang Y-C, Yuan C-Y, Liu C-Y, et al. Vibrio vulnificus infection in Taiwan: Report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis. 1992;15:271–6.PubMedCrossRef
25.
Howard RJ, Bennett NT. Infections caused by halophilic marine Vibrio bacteria. Ann Surg. 1993;217:525–31.PubMedCrossRef
26.
Shapiro RL, Altekruse S, Hutwagner L, the Vibrio Working Group, et al. The role of gulf coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988–1996. J Infect Dis. 1998;178:752–9.PubMedCrossRef
27.
Kuo Y-L, Shieh S-J, Chiu H-Y, Lee J-W. Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention. Eur J Clin Microbiol Infect Dis. 2007;26:785–92.PubMedCrossRef
28.
Hsueh P-R, Lin C-Y, Tang H-J, et al. Vibrio vulnificus in Taiwan. Emerg Infect Dis. 2004;10:1363–8.PubMed
29.
Forbes BA, Sahm DF, Weissfeld AS. Vibrio, Aeromonas, Pleisiomonas, Shigelloides, and Chromobacterium violaceum. In: Forbes BA, Sahm DF, Weissfeld AS, editors. Bailey & Scott’s diagnostic microbiology. 11th ed. St. Louis: Mosby, Inc.; 2002. p. 423–33.
30.
Muldrew KL, Simpson JF, Stratton CW, Tang YW. Molecular diagnosis of necrotizing fasciitis by 16S rRNA gene sequencing and superantigen gene detection. J Mol Diagn. 2005;7:641–5.PubMedCrossRef
31.
Lee C-H, Wang C-C, Yue C-T et al. Necrotizing fasciitis caused by Vibrio vulnificus in a man with cirrhosis. Lancet Infect Dis. 2008;399.
32.
Chuang Y-C, Liu J-W, Ko W-C, et al. In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother. 1997;41:2214–7.PubMed
33.
Tang H-J, Chang M-C, Ko W-C, et al. In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother. 2002;46:3580–4.PubMedCrossRef
34.
Chuang Y-C, Ko W-C, Wang S-T, et al. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother. 1998;42:1319–22.PubMed
35.
The Sandford guide to antimicrobial therapy. In: Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS, editors. 40th ed; 2010. p. 51.
36.
Jones BL, Wilcox MH. Aeromonas infections and their treatment. J Clin Microbiol. 1995;35:453–61.
37.
Tsai Y-H, Hsu RW-W, Huang T-J, et al. Necrotizing soft-tissue infections and sepsis caused by Vibrio vulnificus compared with those caused by Aeromonas species. J Bone Joint Surg Am. 2007;89:631–6.PubMedCrossRef
38.
Gold WL, Salit IE. Aeromonas hydrophila infections of skin and soft tissue: report of 11 cases and review. Clin Infect Dis. 1993;16:69–74.PubMedCrossRef
39.
Janda JM. Recent advances in the study of the taxonomy, pathogenicity and infectious syndromes associated with the genus aeromonas. Clin Microbiol Rev. 1991;4:397–410.PubMed
40.
Ghenghesh KS, Ahmed SF, El-Khalek RA, et al. Aeromonas-associated infections in developing countries. J Infect Developing Countries. 2008;2:81–98.CrossRef
41.
Steinberg JP, Burd EM. Other gram-negative and gram-variable bacilli. Aeromonas species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Elsevier; 2010. pp. 3017–9.
42.
•• Janda JM, Abbott SL. The genus Aeromonas: taxonomy pathogenesis and infection. Clin Microbiol Rev. 2010;23:35–73. This is the more recent and thorough review on Aeromonas infection. PubMedCrossRef
43.
Lamy B, Kodjo A, Laurent F. Prospective nationwide study of Aeromonas infections in France. J Clin Microbiol. 2009;47:1234–7.PubMedCrossRef
44.
Davis II WA, Kane JG, Garagusi VF. Human Aeromonas infections. A review of the literature and a case report of endocarditis. Medicine. 1978;57:267–77.PubMedCrossRef
45.
Harris RL, Fainstein V, Elting L, et al. Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis. 1985;7:314–20.PubMedCrossRef
46.
Martino R, Santamaria A, Pericas R, et al. Acute rhabdomyolysis and myonecrosis complicating aeromonas bacteremia in neutropenic patients with hematologic malignancies: report of two cases. Haematologica. 1997;82:692–4.PubMed
47.
Hanson PG, Standridge J, Jarret F, Maki DG. Freshwater wound infection due to aeromonas hydrophila. JAMA. 1977;238:1053–4.PubMedCrossRef
48.
Hiransuthikul N, Tantisirivat W, Lertutsahakul K, et al. Skin and soft-tissue infections among Tsunami survivors in southern Thailand. Clin Infect Dis. 2005;41:e93–6.PubMedCrossRef
49.
Ribeiro NFF, Heath CH, Kierath J, et al. Burn wounds infected by contaminated water: case reports, review of the literature and recommendations for treatment. Burns. 2010;36:9–22.PubMedCrossRef
50.
Tena D, Gonzales-Praetorius A, Gimeno C, et al. Rapidly progressive myonecrosis by Aeromonas veronii biotype sobria. An Med Interna. 2006;23:540–2.PubMed
51.
Bauters TG, Buyla FM, Verschraegen G, et al. Infection risk related to the use of medicinal leeches. Pharm World Sci. 2007;29(3):122–5.PubMedCrossRef
52.
Sartor C, Limouzin-Perotti F, Legre R, et al. Nosocomial infections with Aeromonas hydrophila from leeches. Clin Infect Dis. 2002;35:e1–5.PubMedCrossRef
53.
Liu BM, Chandchien CS, Chen CH, et al. Fatal aeromonas hydrophila infection of soft tissue after endoscopic injection sclerotherapy for gastric variceal bleeding. Chang Gung Med J. 2004;27(10):766–9.PubMed
54.
Derby HA, Hammer HA. Bacteriology of butter. IV. Bacteriological studies on surface taint butter. Iowa Agric Exp Station Res Bull. 1931;145:389–416.
55.
Long HF, Hammer BW. Classification of organisms important in dairy products. III. Pseudomonas putrefaciens. Iowa Agric Exp Station Res Bull. 1941;285:176–95.
56.
MacDonell MT, Colwell RR. Phylogeny of the Vibrionaceae, and recommendation for two new genera, Listonella and Shewanella. Syst Appl Microbiol. 1985;6:171–82.
57.
Holt HM, Gahrn-Hansen B, Bruun B. Shewanella algae and Shewanella putrefaciens: clinical and microbiological characteristics. Clin Microbiol Infect. 2005;11:347–52.PubMedCrossRef
58.
Kueh HC, Kutarski P, Brunton M. Contaminated marine wounds—the risk of acquiring acute bacterial infection from marine recreational beaches. J Appl Bacteriol. 1992;73:412–20.PubMed
59.
Oh HS, Kum KA, Kim EC, et al. Outbreak of Shewanella algae and Shewanella putrefaciens infections caused by a shared measuring cup in a general surgery unit in Korea. Infect Control Hosp Epidemiol. 2008;29:742–8.PubMedCrossRef
60.
Tsai MS, You HL, Tang YF, Liu JW. Shewanella soft tissue infection: case report and literature review. Int J Infect Dis. 2008;12:e119–24.PubMedCrossRef
61.
Tsai TH, You HY. Nectotyzing fasciitis caused by shewanella putrefaciens in a uremic patient. J Microbiol Immunol Infect. 2006;39:516–8.PubMed
62.
Sharma KK, Kalawat U. Emerging infections: Shewanella—a series of five cases. J Lab Physicians. 2010;2:61–5.PubMedCrossRef
63.
Chen Y, Liu Y, Yen M, et al. Skin and soft-tissue manifestations of Shewanella putrfaciens infection. Clin Infect Dis. 1997;25:225–9.PubMedCrossRef
64.
Pagani L, Lang A, Vedovelli C, et al. Soft tissue infecctions and bacteremia caused by Shewanella putrefaciens. J Clin Microbiol. 2003;41(5):2240–1.PubMedCrossRef
65.
Botelho-Nevers E, Gouriet F, Rovery C, et al. First case of osteomyelitis due to Shewanella algae. J Clin Microbiol. 2005;43(10):5388–90.PubMedCrossRef
66.
Ternavasio-de-la-Vega HG, Angel-Moreno A, Hernández-Cabrera M, et al. Skin and soft tissue infections (patera foot) in immigrants, Spain. Emerg Infect Dis. 2009;15(4):598–600.PubMedCrossRef
67.
Bring IJ, van Staten A, van Rensburg AJ. Shewanella (pseudomonas) putrefaciens bacteremia. Clin Infect Dis. 1995;20:1327–32.CrossRef
68.
Appelbaum PC, Bowen AJ. Opportunistic infection of chronic skin ulcers with Pseudomonas putrefaciens. Br J Dermatol. 1978;98:229–31.PubMedCrossRef
69.
Domínguez H, Vogel BF, Gram L, et al. Shewanella alga bacteremia in two patients with lower leg ulcers. Clin Infect Dis. 1996;22:1036–9.PubMedCrossRef
70.
Kim JH, Cooper RA, Welty WK, et al. Pseudomonas putrefaciens bacteremia. Rev Infect Dis. 1989;11:97–104.PubMedCrossRef
71.
Pope TL, Teague WG, Kossack R, et al. Pseudomonas sacroiliac osteomyelitis: diagnosis by gallium citrate Ga 67 scan. Am J Dis Child. 1982;136(7):649–50.PubMed
72.
73.
Laudat P, Audurier A, Loulergue F, et al. Pseudomonas putrefaciens meningitis. J Infect. 1983;7(3):281–3.PubMedCrossRef
74.
'Süzük S, Yetener V, Ergüngör F, Balaban N. Cerebellar abscess caused by Shewanella putrefaciens. Scand J Infect Dis. 2004;36(8):621–2.PubMedCrossRef
75.
Dhawan B, Chaudhry R, Mishra BM, Agarwal R. Isolation of Shwanella purtrefaciens from a rheumatic heart disease patient with infective endocarditis. J Clin Microbiol. 1998;36:2394.PubMed
76.
Butt AA, Figueroa J, Martin DH. Ocular infection caused by three unusual marine organisms. Clin Infect Dis. 1997;24:740.PubMedCrossRef
77.
Kueh HC, Kutarski P, Brunton M. Contaminated marine wounds-the risk of acquiring acute bacterial infection from marine recreational beaches. J Appl Bacteriol. 1992;73:412–20.PubMed
78.
Roger SD, Chen SC, Lawrence S, Sorrell TC. Pseudomonas purtrefaciens bacteremia in a peritoneal dialysis patient. Nephrol Dial Transplant. 1991;6:73.PubMed
79.
Chen SC, Lawrence RH, Packham DR, Sorell TC. Cellulitis due to pseudomonas purtrefaciens: possible production of exotoxins. Rev Infect Dis. 1991;13(4):642–3.PubMedCrossRef
80.
Holt HM, Gahrn-Hansen B, Braun B. Shewanella species: infections in Denmark and phenotypic characterization. Clin Microbiol Infect. 2004;20 suppl 3:343–9.
81.
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.PubMedCrossRef
82.
Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis. 2009;15:1351–8.PubMedCrossRef
83.
Falkinham JO. Epidemiology of infection by nontuberculosis mycobacteria. Clin Microbiol Rev. 1996;9:177–215.PubMed
84.
Wagner D, Young LS. Nontuberculous mycobacterial infections: a clinical review. Infection. 2004;32:257–70.PubMedCrossRef
85.
Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med. 2002;162(15):1746–52.PubMedCrossRef
86.
87.
Danko JR, Gilliland WR, Miller RS, Decker CF. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Scand J Infect Dis. 2009;41:252–5.PubMedCrossRef
88.
Imakado S, Kojima Y, Hiyoshi T, Morimoto S. Disseminated Mycobacterium marinum infection in a patient with diabetic nephropathy. Diabetes Res Clin Pract. 2009;83(2):e35–6.PubMedCrossRef
89.
Casal M, Casal MM, Spanish Group of Mycobacteriology. Multicenter study of incidence of Mycobacterium marinum in humans in Spain. Int J Tuberc Lung Dis. 2001;5:197–9.PubMed
90.
Liao CH, Lai CC, Ding LW, et al. Skin and soft tissue infection caused by non-tuberculous mycobacteria. Int J Tuberc Lung Dis. 2007;11(1):96–102.PubMed
91.
Chen HY, Chen CY, Huang CT, et al. Skin and soft-tissue infection caused by non-tuberculous mycobacteria in Taiwan, 1997–2008. Epidemiol Infect. 2011;139(1):121–9.PubMedCrossRef
92.
Agnew W, Barnes AC. Streptococcus iniae: An aquatic pathogen of global veterinary significance and a challenging candidate for reliable vaccination. Vet Microbiol. 2007;122:1–15.PubMedCrossRef
93.
Peir GB, Madin SH. Streptococcus iniae sp. nov., a betahemolytic streptococcus isolated from an Amazon freshwater dolphin, Inia geoffrensis. Int J Syst Bacteriol. 1976;26:545–53.CrossRef
94.
Weinstein MR, Litt M, Kertesz DA, et al. Invasive infections due to a fish pathogen, Streptococcus iniae. S.iniae study group. N Engl J Med. 1997;337:589–94.PubMedCrossRef
95.
Hansen GR, Woodall J, Brown C, et al. Emerging zoonotic diseases. Panel summary from the International Conference on Emerging Infectious Diseases Conference, Atlanta, Georgia, 2000. Emerg Infect Dis. 2001;7:537.PubMedCrossRef
96.
Sun J-R, Yan J-C, Yeh C-Y, et al. Invasive infection with Streptococcus iniae in Taiwan. J Med Microbiol. 2007;56:1246–9.PubMedCrossRef
97.
Koh TH, Sng LH, Yuen SM, et al. Streptococcal cellulitis following preparation of fresh raw seafood. Zoonoses Public Health. 2009;56:206–8.PubMedCrossRef
98.
Lau SKP, Woo PCY, Tse H, et al. Invasive Streptococcus iniae infections outside North America. J Clin Microbiol. 2003;41:1004–9.PubMedCrossRef
99.
Facklam R, Elliott J, Shewmaker L, Reingold A. Identification and characterization of sporadic isolates of Streptococcus iniae isolated from humans. J Clin Microbiol. 2005;43:933–7.PubMedCrossRef
100.
Fuller JD, Bast DJ, Nizet V, et al. Streptococcus iniae virulence is associated with a distinct genetic profile. Infect Immun. 2001;69:1994–2000.PubMedCrossRef
101.
Reboli AC. Erysipelothrix rhusiopathiae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Elsevier; 2010. pp. 2733–5.
102.
Wood RL. Erysipelothrix infection. In: Hubbert WT, McCullough WF, Schnurrenberger PR, editors. Diseases transmitted from animals to man. 6th ed. Springfield: Thomas; 1975. p. 271–81.
103.
• Tlougan BE, Podjasel JO, Adams BB. Aquatic sport dermatoses: part 3 on the water. Int J Dermatol. 2010;49:1111–20. This is one of a three-part comprehensive series on water-related dermatologic conditions seen in people participating in aquatic activities. PubMedCrossRef
104.
Nelson E. Five hundred cases of erysipeloid. Rocky Mtn Med J. 1955;52:40–2.
105.
Collier DN. Cutaneous infections from coastal and marine bacteria. Dermatol Ther. 2002;15:1–9.CrossRef
106.
107.
Hocqueloux L, Poisson DM, Sunder S, et al. Septic arthritis caused by Erysipelothrix rhusiopathiae in a prosthetic knee joint. J Clin Microbiol. 2010;48:333–5.PubMedCrossRef
108.
Brooke CJ, Riley TV. Erysipelothrix rhusiopathiae: bacteriology, epidemiology and clinical manifestations of an occupational pathogen. J Med Microbiol. 1999;48:789–99.PubMedCrossRef
109.
Fidalgo SG, Riley TV. Detection of Erypelothrix rhusiopatieae in clinical and environmental samples. Methods Mol Biol. 2004;268:199–205.PubMed
110.
Reboli AC, Farrar WE. The genus Erysipelothrix. In: Balows A, Truper HG, Dworkin M, Harder W, Schleifer K, editors. The Prokaryotes. A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications. New York: Springer; 1992. p. 1629–42.
Metadata
Title
Soft Tissue Infections Caused by Marine Bacterial Pathogens: Epidemiology, Diagnosis, and Management
Authors
Renato Finkelstein
Ilana Oren
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0199-3

Other articles of this Issue 5/2011

Current Infectious Disease Reports 5/2011 Go to the issue

ReviewPaper

When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock

ReviewPaper

Antibiotic Therapy in Neonatal and Pediatric Septic Shock

ReviewPaper

When and How to Cover for Resistant Gram-Negative Bacilli in Severe Sepsis and Septic Shock

ReviewPaper

Recent Advances in the Treatment of Necrotizing Fasciitis

ReviewPaper

What’s New in the Management of Bacterial Septic Arthritis?

ReviewPaper

Early and Adequate Antibiotic Therapy in the Treatment of Severe Sepsis and Septic Shock
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits